NCT05417126View on ClinicalTrials.gov

Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

August 2, 2023

Study Completion Date

September 28, 2023

Conditions
Stargardt Disease
Interventions
BIOLOGICAL

Gene Therapy-vMCO-010

The vMCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

Trial Locations (2)

33136

Nanoscope Clinical Site, Miami

78503

Nanoscope Clinical Site, McAllen

Sponsors
All Listed Sponsors
lead

Nanoscope Therapeutics Inc.

INDUSTRY

NCT05417126 - Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease | Biotech Hunter | Biotech Hunter